Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allylamine SCHEMBL2214884 | 1.00 | MCL1 (0.65) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL15082 | 0.88 | MCL1 (0.76) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL8773598 | 0.88 | MCL1 (0.76) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL15081 | 0.88 | MCL1 (0.76) | MCL1LMNAKDM4EHTTALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL434911 | 0.87 | MCL1 (0.73) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL9361168 | 0.82 | MCL1 (0.67) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL9361177 | 0.82 | MCL1 (0.67) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL9508065 | 0.82 | MCL1 (0.65) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL10938245 | 0.79 | MCL1 (0.62) | MCL1LMNAKDM4EHTTALDH1A1 | |
| SCHEMBL14889223 | 0.79 | MCL1 (0.71) | MCL1LMNAKDM4EHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4649155-A2 | COMPOSITIONS AND METHODS FOR TREATING A NEUROLOGIC DISEASE USING DOPAMINERGIC NEURONS WITH ENHANCED ANTI-INFLAMMATORY ACTIVITY | Kenai Therapeutics Inc. (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4231015-B1 | METHODS FOR DIFFERENTIATING AND PURIFYING PANCREATIC ENDOCRINE CELLS | KADIMASTEM LTD (IL) | 2024-10-30 | — | — | EP | disclosed |
| US-20240325456-A1 | MULTIPOTENT LUNG PROGENITOR CELLS FOR LUNG REGENERATION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-10-03 | — | — | US | disclosed |
| CN-118696122-A | Multipotent lung progenitor cells for lung regeneration | 耶达研究及发展有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024182311-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | RYNE BIOTECHNOLOGY INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| WO-2024151776-A2 | COMPOSITIONS AND METHODS FOR TREATING A NEUROLOGIC DISEASE USING DOPAMINERGIC NEURONS WITH ENHANCED ANTI-INFLAMMATORY ACTIVITY | RYNE BIOTECHNOLOGY INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12016876-B2 | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-06-25 | — | — | US | disclosed |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| EP-4277635-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | Yeda Research and Development Co. Ltd (IL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2013121426-A1 | CULTURING OF MESENCHYMAL STEM CELLS | GAMIDA-CELL LTD. (IL) | 2013-08-22 | — | — | WO | disclosed |
| US-8492329-B2 | Bioactive peptides and methods of using same | COMPUGEN LTD. (IL) | 2013-07-23 | — | — | US | disclosed |
| CN-103210082-A | Methods of expanding and redifferentiating islet beta cells | UNIV RAMOT | 2013-07-17 | — | — | CN | disclosed |
| EP-2167534-B1 | BIOACTIVE PEPTIDES AND METHOD OF USING SAME | COMPUGEN LTD (IL) | 2012-07-04 | — | — | EP | disclosed |
| CN-102282249-A | Adherent cells from placental tissue and their use in therapy | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110177998-A1 | BIOACTIVE PEPTIDES AND METHODS OF USING SAME | COMPUGEN LTD. (IL) | 2011-07-21 | — | — | US | disclosed |
| CN-102123717-A | Methods of treating inflammatory colon diseases | PLURISTEM LTD | 2011-07-13 | — | — | CN | disclosed |
| EP-2167534-A2 | BIOACTIVE PEPTIDES AND METHOD OF USING SAME | Compugen Ltd. (IL) | 2010-03-31 | — | — | EP | disclosed |
| CN-101558151-A | Cell expansion methods and uses of cells and conditioned media produced thereby for therapy | PLURISTEM LTD (IL) | 2009-10-14 | — | — | CN | disclosed |
| WO-2009007848-A2 | BIOACTIVE PEPTIDES AND METHOD OF USING SAME | COMPUGEN LTD. (IL) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | MCL1 71/4885LMNA 1808/4885KDM4E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.